ALX Oncology Holdings's Total Assets for the quarter that ended in Dec. 2023 was $242.55 Mil.
During the past 12 months, ALX Oncology Holdings's average Total Assets Growth Rate was 48.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 219.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 115.60% per year.
During the past 6 years, ALX Oncology Holdings's highest 3-Year average Total Assets Growth Rate was 219.40%. The lowest was 78.50%. And the median was 189.60%.
Total Assets is connected with ROA %. ALX Oncology Holdings's annualizedROA % for the quarter that ended in Dec. 2023 was -78.63%. Total Assets is also linked to Revenue through Asset Turnover. ALX Oncology Holdings's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
ALX Oncology Holdings Total Assets Historical Data
The historical data trend for ALX Oncology Holdings's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ALX Oncology Holdings Annual Data
Trend
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
10.68
436.05
380.18
306.49
242.55
ALX Oncology Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
306.49
278.14
245.93
220.11
242.55
ALX Oncology Holdings Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ALX Oncology Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (NAS:ALXO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ALX Oncology Holdings's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ALX Oncology Holdings Total Assets Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 